ALK Abello licenses rights to neffy from ARS Pharma

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) has entered into a strategic license agreement with US-based ARS Pharmaceuticals (Nasdaq: SPRY).

The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions, the company pointed out.

ALK notes that neffy is the first and only approved needle-free emergency treatment for patients experiencing acute and potentially life-threatening allergic reactions. The European Commission granted EURneffy (the trade name for neffy in the European Union) market authorization in the EU in August 2024. Furthermore, neffy was approved by the US Food and Drug Administration also in August 2024, and was launched in the USA in September. Submission for regulatory approval in Canada is planned for by the end of 2024.